GE updates Signa platform
The latest evolution of GE Healthcare's Signa HD x (high definition x) platform offers MR pulse sequences that overcome barriers to diagnostic scans in some difficult-to-image patients. The xt version, shown at the RSNA meeting, features two major innovations: 3D Cube and Ideal.
The latest evolution of GE Healthcare's Signa HD x (high definition x) platform offers MR pulse sequences that overcome barriers to diagnostic scans in some difficult-to-image patients. The xt version, shown at the RSNA meeting, features two major innovations: 3D Cube and Ideal. 3D Cube's capture of submillimeter isotropic voxels allows the viewing of a volumetric data set in any plane and the visualization of lesions as small as 2 mm. Ideal improves image clarity through uniform fat suppression and handling multiple contrasts from fat, water, and the two combined, both in-phase and out-of-phase. It also reduces or eliminates artifacts due to chemical shift of metal implants, such as orthopedic screws or dental work, and eliminates misregistration between fat and water.
MRI Study at ARRS Raises Questions About Disparities in Detection of MASLD
May 3rd 2025New research revealed that Hispanic Americans with evidence of hepatic steatosis on MRI but no formal diagnosis of MASLD had over a fourfold higher risk of developing hepatocellular carcinoma in comparison to those who had a formal diagnosis of MASLD.
Emerging AI Algorithm Shows Promise for Abbreviated Breast MRI in Multicenter Study
April 25th 2025An artificial intelligence algorithm for dynamic contrast-enhanced breast MRI offered a 93.9 percent AUC for breast cancer detection, and a 92.3 percent sensitivity in BI-RADS 3 cases, according to new research presented at the Society for Breast Imaging (SBI) conference.
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
